Acute Heart Failure: Current Standards and Evolution of Care
Source: Acute Heart Failure: Current Standards and Evolution of Care

Video Module

In this CME-certified interactive online program, G. Michael Felker, MD, MHS, FACC, FAHA, and Javed Butler, MD, MPH, MBA, discuss recent data concerning the diagnosis and management of acute heart failure, including the use of biomarkers in diagnosis and prognosis, benefits and limitations of current standards of care, and evidence regarding investigational therapeutics.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of biomarkers in the diagnosis and management of patients with acute heart failure
  • Assess the benefits and limitations of the current standard of care for the treatment of acute heart failure
  • Differentiate between acute heart failure with reduced ejection fraction and preserved ejection fraction and describe how each affects patient management
  • Describe emerging therapies for acute heart failure and be able to incorporate them appropriately into the clinical management of patients
  • Nurses will be better able to provide appropriate care and counsel for patients and their families
  • Pharmacists will be better able to provide accurate and appropriate counsel as part of the treatment team

 

Topics include:

  • Biomarkers in Diagnosis and Prognosis
  • Clinical Considerations
  • Current Treatment Options
  • Investigational Agents
CCO Video Modules contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Faculty

  • G. Michael Felker
    MD, MHS, FACC, FAHA
    Javed Butler
    MD, MPH, MBA

Credit Information

  • Release Date:
    July 24, 2015
  • Expiration Date:
    July 23, 2016
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit
  • Registered Nurses:
    1.0 Nursing contact hour
  • Pharmacists:
    1.0 contact hour (0.1 CEUs)

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

G. Michael Felker, MD, MHS, FACC, FAHA


Professor of Medicine
Chief
, Heart Failure Section
Division of Cardiology
Duke University
Durham, North Carolina

G. Michael Felker, MD, MHS, FACC, FAHA, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celladon, Merck, Novartis, Relypsa, Roche Diagnostics, Singulex, Stealth Peptides, and Trevena and funds for research support from Amgen, Novartis, Otsuka, and Roche Diagnostics.
 

Javed Butler, MD, MPH, MBA


Professor of Medicine
Chief of Cardiology
Division of Cardiology
Stony Brook University
Stony Brook, New York

Javed Butler, MD, MPH, MBA, has disclosed that that he has received consulting fees from Amgen, Bayer, Cardiocell, Celladon, Novartis, Stealth Peptides, Trevena, Zensun, and ZS Pharma and fees for non-CME/CE services from Novartis.
 

Staff

Ryan P. Topping, PhD


Associate Managing Editor

Ryan Topping, PhD, has no real or apparent conflicts of interest to report.
 

Kiran Mir-Hudgeons, PhD


Clinical Editor

Kiran Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This activity is intended for cardiologists, hospitalists, internists, family physicians, registered nurses, nurses, pharmacists, and other clinicians caring for patients with acute heart failure.


Goal

The goal of this activity is to improve learners’ knowledge of current best practices and emerging approaches in the management of acute heart failure.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of biomarkers in the diagnosis and management of patients with acute heart failure
  • Assess the benefits and limitations of the current standard of care for the treatment of acute heart failure
  • Differentiate between acute heart failure with reduced ejection fraction and preserved ejection fraction and describe how each affects patient management
  • Describe emerging therapies for acute heart failure and be able to incorporate them appropriately into the clinical management of patients
  • Nurses will be better able to provide appropriate care and counsel for patients and their families
  • Pharmacists will be better able to provide accurate and appropriate counsel as part of the treatment team
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nursing Continuing Education

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.

 

Pharmacist Continuing Education

Accreditation Statement

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - 0809-9999-15-239-H01-P)

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

 

Commercial Support


This program is supported by educational grants from Amgen, and Novartis Pharmaceuticals Corporation.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 24, 2015, through July 23, 2016:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.